LifeCare Partners
VC Fund
Basel, Switzerland
LifeCare Partners is a VC fund in Basel focused on Biotechnology and Medical. LifeCare Partners provides private equity and mezzanine financing
- Total investments:
- 11
- Last investment:
- Lead investor:
- 64%
Last updated:
For AI agents: llms.txt
Industries LifeCare Partners invests in
BiotechnologyMedicalHealth CareSoftwareMedical Device
Stages LifeCare Partners invests in
Series AFunding RoundPost-IPO Equity
Countries LifeCare Partners invests in
GermanySwitzerlandUnited States
Round sizes
Series A $4.1M–$19M
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Series A
- $4.1M–$19M
Investment Focus
Industry
- Biotechnology 5 (45%)
- Medical 4 (36%)
- Health Care 4 (36%)
- Software 2 (18%)
- Medical Device 2 (18%)
Stage
- Series A 5 (45%)
- Funding Round 2 (18%)
- Post-IPO Equity 1 (9%)
Country
- Germany 3 (27%)
- Switzerland 2 (18%)
- United States 1 (9%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Gerhard Ries
General Partner
|
General Partner | Total investments: 10 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Kupando
|
Kupando is a biopharmaceutical company that develops agonists to stimulates innate immunity. | $11.5M / Series A / Mar 18, 2026 | |
|
Kupando
|
Kupando is a biopharmaceutical company that develops agonists to stimulates innate immunity. | $12.5M / Series A / Sep 26, 2022 | |
b-rayZ
|
b-rayZ is a spin-off of the University Hospital Zurich. Their team consists of professional radiologists, data scientists and physicians, with more than 15 years of work experience in medical imaging and radiology. They develop and provide predictive deep learning analytical tools and algorithms for the assessment of your personal medical images. | $4.1M / Series A / Jul 07, 2022 | |
NeoPrediX
|
NeoPrediX develops decision support tools with maternal, neonatal and perinatal screening platforms to evaluate, optimize and personalize medical strategies in pediatrics. We utilize intelligent algorithms and digital health solutions for neonatal and perinatal care based on deep medical data and science, developed by experienced scientists,pediatricians, and neonatologists. We transform medical data into intelligent predictions to support clinical decisions. | $4.8M / Mar 17, 2021 | |
|
NeoPrediX
|
NeoPrediX develops decision support tools with maternal, neonatal and perinatal screening platforms to evaluate, optimize and personalize medical strategies in pediatrics. We utilize intelligent algorithms and digital health solutions for neonatal and perinatal care based on deep medical data and science, developed by experienced scientists,pediatricians, and neonatologists. We transform medical data into intelligent predictions to support clinical decisions. | $4.4M / Series A / Mar 17, 2021 | |
Immunic Therapeutics
|
Immunic, Inc. is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolismof activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. | $11M / Series A / Sep 05, 2017 | |
|
Immunic Therapeutics
|
Immunic, Inc. is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolismof activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. | Series A / Feb 01, 2017 | |
|
Immunic Therapeutics
|
Immunic, Inc. is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolismof activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. | $19.2M / Series A / Sep 27, 2016 | |
Kuros Biosciences
|
Kuros Biosciences AG is a Swiss-based company focused on the development of innovative products for tissue repair and regeneration.Founded in 2000 as a spin-off of the Eidgenössische Technische Hochschule Zürich (ETHZ), Kuros has developed a pipeline of products based upon its proprietary technology platforms. These platforms were developed fromwork carried out at ETHZ, at the University of Zürich and at the California Institute of Technology (CalTech). In addition, in early 2017 Kuros acquired Xpand Biotechnology to gain access to its MagnetOs family of bone graft substitutes and the associated surface science technology.Kuros has attractive commercial prospects in key market segments as well as an EU hub for future clinical and distribution operations. The company is in transition to commercial stage with one product having marketing approval in the EU and US and further product expected to achieve EU approval this year. MagnetOs is approved for sale in the EU for orthopedic, spine and dental applications, and in the US for posterolateral spinal fusion. In addition, a putty formulation is being prepared for submission in the EU and the US in the second half of this year. Neuroseal, a novel biomaterial for dural sealing, is Kuros’ second product and currently under review for CE marking in the EU.Kuros has also assembled a pipeline of clinical stage programs in various stages of development and amassed significant clinical and preclinical data in a number of indications and applications primarily in the area of orthobiologics. The Company has enrolled over 600 patients in multinational clinical trials, and has generated promising safety and efficacy in a number of significant indications. | $15.4M / Post-IPO Equity / Aug 18, 2015 | |
leon nanodrugs
|
leon nanodrugs a specialised product development company dedicated to developing a pipeline of enhanced versions of existing drug products, and providing services to enable pre-clinical and clinical stage formulations for their clients NCEs or branded established drugs.leon-nanodrugs offers access to the next generation of nano-formulated drugswith meaningful differentiation and added patient benefits.They specialize in improving the bioavailability of poorly water soluble drugs by using leon’s proprietary MJR® Technology platform to create either polymeric or crystalline nanoparticles. | Series A / Jul 27, 2015 | |
| See all 11 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
SaaS Investors
99,274 investors
Software Investors
50,021 investors
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Medical Device Investors
11,047 investors
SaaS VC Funds
61,208 investors
Software VC Funds
31,919 investors
FAQ
What does LifeCare Partners invest in?
LifeCare Partners invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Funding Round stage. Most of the 11 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is LifeCare Partners's check size?
LifeCare Partners typically joins rounds of $4.1M–$19M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds LifeCare Partners participates in.
How do I contact LifeCare Partners?
Public channels for LifeCare Partners include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at LifeCare Partners?
The team at LifeCare Partners includes Gerhard Ries (General Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
